Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | DNM2 | P50570 | 2/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4781035 | 0.77 | PRKCQ (0.43) | HRH4HRH3PRKCQPRKCDNMT1 | |
| SCHEMBL2948693 | 0.76 | HRH4 (0.55) | HRH4HRH3DNM2HRH2AURKA | |
| SCHEMBL4776496 | 0.74 | PRKCQ (0.44) | HRH4PRKCQPRKCDNMT1HDAC1 | |
| SCHEMBL1775168 | 0.74 | HRH4 (0.54) | HRH4HRH3HRH2PRKCQPRKCD | |
| SCHEMBL1773333 | 0.74 | HRH4 (0.54) | HRH4HRH3HRH2PRKCQPRKCD | |
| SCHEMBL4846681 | 0.70 | PRKCQ (0.38) | HRH4PRKCQPRKCDNMT1HDAC1 | |
| SCHEMBL4781169 | 0.68 | PRKCQ (0.47) | PRKCQPRKCDNMT1HDAC1ROCK2 | |
| SCHEMBL14186227 | 0.67 | NMT1 (0.52) | PRKCQPRKCDNMT1HDAC1ROCK2 | |
| SCHEMBL12410840 | 0.66 | DNM2 (0.57) | HRH4HRH3DNM2AURKAKIT | |
| SCHEMBL1774878 | 0.65 | HRH4 (0.71) | HRH4HRH3PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | HRH4 817/4885HRH3 1026/4885DNM2 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.